ESMO WCGIC 2023 | AN0025 with chemoradiotherapy in advanced rectal cancer

Lucjan Wyrwicz, MD, PhD, Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, Poland, provides an overview of a Phase I trial (NCT03152370) of AN0025, an EP4 inhibitor, with total neoadjuvant treatment in patients with advanced rectal cancer. Patients received AN0025 with either short course (SCRT) or long course radiotherapy (LCRT) and radiotherapy. Addition of AN0025 did not increase toxicity, and the findings warrant further study. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.